evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,454 questions · 3,562 findings · 816 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 538 · 15.1%GRADE not reported 239 · 6.7%Very low 933 · 26.2%Low 1,041 · 29.2%Moderate 612 · 17.2%High 199 · 5.6%

Intravenous tranexamic acid vs placebo

Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether intravenous tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review

Intravenous tranexamic acid vs placebo

Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether intravenous tranexamic acid changes risk of suspected serious drug reactions (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo

Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether topical tranexamic acid changes risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo

All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel dressings vs OCT‐free placebo hydrogel dressings

Donor site healing time in days for adults · adults with skin graft donor sites

It is very uncertain whether summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel… changes time to complete wound healing of skin graft donor sites (days)… compared with OCT‐free placebo hydrogel dressings (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

All‐cause mortality at up to day 28 ‐ total · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 ‐ total compared with placebo or standard care alone (high certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs human immunoglobulin

All‐cause mortality at up to day 28 · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 compared with human immunoglobulin (low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

All‐cause mortality at up to day 28 · outpatients withmild disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with placebo or standard care alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in clinical worsening: need for invasive mechanical ventilation, or… compared with placebo or standard care alone (high certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Admission to hospital or death within 28 days · outpatients withmild disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard care alone (low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Time to symptom resolution · outpatients withmild disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in time to symptom resolution (absolute effect calculated for day 12) compared with placebo or standard care alone (low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs standard plasma

All‐cause mortality at up to day 28 · outpatients withmild disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with standard plasma (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs standard plasma

Admission to hospital or death within 28 days · outpatients withmild disease

Summary of findings table ‐ Convalescent plasma probably leads to lower admission to hospital or death within 28 days compared with standard plasma (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs standard plasma

All‐cause mortality at up to day 28 · individuals with moderate to severe disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with standard plasma (very low certainty).

1 finding from 1 review